BC Week In Review | Jun 29, 2015
Company News

CytoSorbents, AlphaMedix deal

CytoSorbents granted AlphaMedix exclusive rights to develop and commercialize CytoSorb for critical care and cardiac surgery applications in Israel. AlphaMedix will be responsible for obtaining regulatory approval. The extracorporeal cytokine filtration device is approved in...
BC Week In Review | Feb 16, 2015
Company News

CytoSorbents, Aferetica deal

CytoSorbents granted Aferetica exclusive, Italian distribution rights to CytoSorb cytokine reduction therapy for critical care applications. The extracorporeal cytokine filtration device has CE Mark approval for indications in which cytokines are elevated, including sepsis and...
BC Week In Review | Nov 24, 2014
Company News

CytoSorbents, Biocon deal

Biocon and CytoSorbents expanded their 2013 deal and Biocon will now have exclusive, distribution rights in India and undisclosed emerging countries to CytoSorbents’ CytoSorb cytokine reduction therapy for all critical care applications in the intensive...
BC Innovations | Sep 18, 2014
Tools & Techniques

Bad blood

Whereas pharmacological approaches to treating sepsis have languished in the clinic, a mechanical approach has been designed by a Massachusetts team that cleanses pathogens and endotoxins from blood. 1 The microfluidic device could be a...
BC Week In Review | Sep 23, 2013
Company News

Biocon, CytoSorbents sales and marketing update

Biocon gained exclusive commercialization rights to CytoSorbents' CytoSorb in India and undisclosed emerging markets. The extracorporeal cytokine filtration device has CE Mark approval for the management of sepsis. The partners could not be reached for...
BC Week In Review | Sep 19, 2011
Clinical News

CytoSorb infectious data

A post hoc analysis of 14 septic patients with elevated levels of IL-6 (>=1,000 pg/mL) or IL-1 receptor antagonist ( IL-1RA ) (>=16,000 pg/mL) from the European Sepsis Trial showed that CytoSorb plus standard of care (SOC)...
Items per page:
1 - 6 of 6